137 related articles for article (PubMed ID: 8463182)
1. Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and Tretinoin.
Górski GK; McMorrow LE; Donaldson MH
In Vitro Cell Dev Biol; 1993 Mar; 29A(3 Pt 1):189-91. PubMed ID: 8463182
[No Abstract] [Full Text] [Related]
2. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate.
Cinatl J; Cinatl J; Herneiz P; Rabenau H; Hovak M; Benda R; Gümbel HO; Kornhuber B; Doerr HW
Cancer Lett; 1994 Apr; 78(1-3):41-8. PubMed ID: 8180967
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate.
Gervelas C; Avramoglou T; Crépin M; Jozefonvicz J
Anticancer Drugs; 2002 Jan; 13(1):37-45. PubMed ID: 11914639
[TBL] [Abstract][Full Text] [Related]
4. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells.
Sidell N; Wada R; Han G; Chang B; Shack S; Moore T; Samid D
Int J Cancer; 1995 Feb; 60(4):507-14. PubMed ID: 7829265
[TBL] [Abstract][Full Text] [Related]
5. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.
Adam L; Crépin M; Isräel L
Cancer Res; 1997 Mar; 57(6):1023-9. PubMed ID: 9067263
[TBL] [Abstract][Full Text] [Related]
6. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer.
Eigelberger MS; Wong MG; Duh QY; Clark OH
Surgery; 2001 Dec; 130(6):931-5. PubMed ID: 11742319
[TBL] [Abstract][Full Text] [Related]
7. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Prasanna P; Thibault A; Liu L; Samid D
J Neurochem; 1996 Feb; 66(2):710-6. PubMed ID: 8592143
[TBL] [Abstract][Full Text] [Related]
8. In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate.
Cinatl J; Cinatl J; Mainke M; Weissflog A; Rabenau H; Kornhuber B; Doerr HW
Cancer Lett; 1993 Jun; 70(1-2):15-24. PubMed ID: 8330296
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interactions between differentiation-inducing agents in inhibiting the proliferation of HL-60 human myeloid leukaemia cells in clonogenic micro assays.
Hassan HT; Veit A; Maurer HR
J Cancer Res Clin Oncol; 1991; 117(3):227-31. PubMed ID: 1709642
[TBL] [Abstract][Full Text] [Related]
10. Neuronal cell differentiation of human neuroblastoma cells by inducing agents in combination.
Rocchi P; Ferreri AM; Simone G; Bagnara GP; Paolucci G
Anticancer Res; 1991; 11(5):1885-9. PubMed ID: 1768060
[TBL] [Abstract][Full Text] [Related]
11. 13cis- and all-trans retinoic acid have antiproliferative effects on CML cells and render IFN alpha antiproliferative potency after combined treatment in vitro.
Benthin M; Dallmann I; Atzpodien J
Cancer Biother Radiopharm; 2001 Aug; 16(4):323-31. PubMed ID: 11603003
[TBL] [Abstract][Full Text] [Related]
12. Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Yata K; Otsuki T; Yamada O; Wada H; Yawata Y; Sugihara T
Int J Hematol; 2002 Jun; 75(5):534-9. PubMed ID: 12095156
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines.
Melichar B; Ferrandina G; Verschraegen CF; Loercher A; Abbruzzese JL; Freedman RS
Clin Cancer Res; 1998 Dec; 4(12):3069-76. PubMed ID: 9865922
[TBL] [Abstract][Full Text] [Related]
14. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
15. Non-clonogenic, in vitro assays for predicting sensitivity to cancer chemotherapy.
Weisenthal LM; Su YZ; Duarte TE; Nagourney RA
Prog Clin Biol Res; 1988; 276():75-92. PubMed ID: 3174684
[No Abstract] [Full Text] [Related]
16. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.
Meco D; Colombo T; Ubezio P; Zucchetti M; Zaffaroni M; Riccardi A; Faircloth G; Jose J; D'Incalci M; Riccardi R
Cancer Chemother Pharmacol; 2003 Aug; 52(2):131-8. PubMed ID: 12783202
[TBL] [Abstract][Full Text] [Related]
17. Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38.
Satoh H; Ishikawa H; Fujimoto M; Fujiwara M; Yamashita YT; Yazawa T; Ohtsuka M; Hasegawa S; Kamma H
Acta Oncol; 1998; 37(1):85-90. PubMed ID: 9572659
[TBL] [Abstract][Full Text] [Related]
18. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate.
Liu L; Shack S; Stetler-Stevenson WG; Hudgins WR; Samid D
J Invest Dermatol; 1994 Sep; 103(3):335-40. PubMed ID: 8077698
[TBL] [Abstract][Full Text] [Related]
20. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate.
Esquenet M; Swinnen JV; Heyns W; Verhoeven G
Prostate; 1996 Mar; 28(3):182-94. PubMed ID: 8628721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
